A high frequency of dysregulation in the chromatin remodelling pathway, especially PBRM1‐inactivating mutations and the PBRM1‐c‐JUN‐VIM axis, served as an important role of cancer invasion and was associated with poor patient outcomes in DPC. This evidence concerns the gene PBRM1 and cancer.